Screener
Immunome IMNM Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 31,106 | 48,845 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 113,171,396 and 113,133,199 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 1,370,678 | 1,362,496 |
| Accumulated deficit | (782,003) | (728,164) |
| Total stockholders’ equity | 588,686 | 634,343 |
| Total liabilities and stockholders’ equity | $619,792 | $683,188 |
Item 1. Financial Statements.
FAQ
- What is Immunome's total liabilities & equity?
- Immunome (IMNM) reported total liabilities & equity of $619.79M in Q1 2026.
- How has Immunome's total liabilities & equity changed year-over-year?
- Immunome's total liabilities & equity increased by 80.9% year-over-year, from $342.69M to $619.79M.
- What is the long-term trend for Immunome's total liabilities & equity?
- Over 5 years (2020 to 2025), Immunome's total liabilities & equity has grown at a 72.7% compound annual growth rate (CAGR), from $44.53M to $683.19M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Immunome's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude